Daily US Equity Opening News - SPCX closes USD 40bln funding for NVDA GPUs; SSNLG & SKHY plan NVDA HBM4 shipments; NFLX & MSFT discuss Xbox licensing; VWAGY plans USD 4bln Georgia investment; BA 777 freighter production halted by supplier dispute

• EVENTS: China’s Fifth Plenum gets underway.
• DATA: In Europe, German Ifo business climate (exp. 89.2, prev. 89.9), expectations (exp. 89.1, prev. 90.4) and current conditions (exp. 89.4, prev. 89.5); UK CBI distributive trades (prev. -55). In North America, US Dallas Fed manufacturing index (prev. 9.8) and Chicago Fed National Activity Index (prev. -0.04).
• CENTRAL BANKS: ECB’s Elderson speaks.
• SUPPLY: US auctions USD 69bln of 2-year notes, and a 20-30-year Treasury buyback announcement; EU sells EUR 7bln of 2029, 2036 and 2051 EU-Bonds.
• EARNINGS: Notable corporate earnings due today include: Verizon (VZ), Welltower (WELL), Cadence Design (CDNS), Nucor (NUE), Public Storage (PSA), Hartford Insurance (HIG), Cincinnati Financial (CINF), Brown & Brown (BRO), Principal Financial Group (PFG), Alexandria Real Estate (ARE).
• WEEK AHEAD: Highlights include: Chinese Fifth Plenum, Israeli legislative election, Fed Policy Announcement, BoC Policy Announcement, RBNZ Policy Announcement, UK Autumn Budget, BoJ Policy Announcement, ECB Policy Announcement, Australian CPI, US GDP (Q3), US PCE (Sep). Notable earnings due this week include: Alphabet (GOOGL), Microsoft (MSFT), Amazon (AMZN), Eli Lilly (LLY), Visa (V), Exxonmobil (XOM), Mastercard (MA), AbbVie (ABBV), Intel (INTC), Chevron (CVX), Coca-Cola (KO), Merck (MRK), Caterpillar (CAT).

• US-Iran - US President Trump said Washington received “two very different sets of intelligence reports” on Iran; he described US intelligence capabilities as “very advanced” and said the US was doing “well with Iran”, without elaborating on the differing assessments. Trump added that he is nearing a decision on whether to negotiate a deal with Iran or resume military strikes, and said finishing the conflict militarily would be “very easy”. Elsewhere, Iran’s Foreign Minister Araghchi proposed a 7-day plan to reopen the Strait of Hormuz, subject to conditions; he added that US military aggression and sanctions remain key obstacles, while energy cooperation with Russia is boosting Iran’s security and exports.
• China-North Korea - North Korean leader Kim Jong Un visited China’s Dandong, meeting senior officials Wang Huning and Wang Yi to strengthen bilateral ties, according to KCNA. Kim honoured Chinese Korean War soldiers and toured an automobile factory. The visit precedes Trump’s November trip to China, amid speculation over potential US-North Korea talks and renewed cross-border trade links.

• US Economy - US President Trump says his administration has further economic announcements planned following Volkswagen’s announcement of a new Audi manufacturing plant in Georgia; he also emphasised the need for additional construction workers.
• China Stocks - China’s state-backed funds recorded CNY 128.7bln in inflows across nine ETFs last week, the largest since April 2025, as authorities sought to stabilise falling equities, according to Bloomberg. Buying helped China’s ChiNext Index rebound on Friday, ending a nine-session losing streak, although the index was under pressure on Monday. Morgan Stanley expects Chinese equities to fall further before valuations bottom as weakening economic growth and consumption weigh on sentiment; its analysts say that offshore shares could decline another 10-15% to around 8 times forward earnings, while mainland equities may fall to valuations of 10-11 times forward earnings.
• Brazil Election - Brazilian President Lula secured a fourth term with 51.79% of votes against Flávio Bolsonaro’s 48.21%, a margin of 3.58 percentage points, according to the BBC. Bolsonaro refused to concede and demanded the election be annulled over extended polling hours, following a controversial two-hour voting extension. Lula faces a deeply divided country and a hostile, right-wing-dominated Congress. Soybean futures fell to a two-month low following Lula’s re-election; his victory has raised expectations of closer Brazil-China trade ties, potentially strengthening Brazil’s position as China’s leading soybean supplier at the expense of US exporters.
• JPY - Goldman Sachs sees JPY becoming a more effective hedge against AI-driven market shocks as Japan’s changing policy backdrop limits depreciation risks. The bank favours short EUR/JPY near term, but sees short USD/JPY as stronger protection against broader risk aversion, particularly if equities and bond yields fall together.
• RBA - RBA Assistant Governor Hunter said the central bank is “not quite yet” done fighting inflation, signalling another potential rate hike on 3rd November.

• US-China - China strongly opposes proposed US Treasury restrictions expanding investment limits on Chinese companies. The Trump administration plans to include biotechnology among sensitive technologies subject to investment curbs, citing national security; Beijing called the measures discriminatory, warned they could harm bilateral trade and US businesses, and reserved the right to retaliate.
• US-Canada - White House adviser Kevin Hassett says US-Canada trade talks are “very close” to a deal; Commerce Secretary Lutnick is set to hold discussions throughout the week.
• UK-EU - PM Burnham is open to discussing restored EU free movement, single-market membership or rejoining the bloc, according to the BBC. Burnham said he is “not proposing re-joining the EU in this parliament”. Any changes would require an electoral mandate, while Burnham opposes joining the Euro or Schengen.

• Samsung Electronics (SSNLG), SK Hynix (SKHY), Nvidia (NVDA) - Samsung and SK Hynix plan to begin mass shipments of 8-layer HBM4 chips to Nvidia in Q2 2027, according to ZDNet Korea. Nvidia is considering using 8-layer HBM4 and HBM4E in Rubin Ultra accelerators amid overheating, yield and supply concerns with 12-layer chips. Both suppliers require separate certification for the 8-layer products.
• Anthropic - Anthropic’s Claude accessed publicly available Georgia voting data without human authorisation, bypassing a paywall during an internal statistics project, according to Axios. The model retrieved aggregate vote counts but did not access voter registration systems or alter records. Anthropic notified Georgia officials and the White House and introduced safeguards to prevent similar incidents.
• Microsoft (MSFT) - Microsoft’s Xbox COO Helen Chiang is leaving the company just months after taking the newly created role, according to The Verge. Chiang spent 21 years at Microsoft, previously leading Minecraft before becoming Xbox COO this summer.
• ASML (ASML) - Vietnam’s first semiconductor plant faces potential delays as military-run Viettel has yet to finalise an equipment agreement with ASML, according to Reuters. The planned site near Hanoi shows no signs of construction, raising doubts over its targeted 2027 trial production. A key outstanding requirement is an ASML deep ultraviolet lithography machine.
• STMicroelectronics (STM) - STM introduced four automotive safety combination sensors designed for mass-market applications, according to the company.

• Netflix (NFLX) - Netflix users are opening the app less frequently and watching less per customer, raising concerns among executives, according to Bloomberg. Engagement has declined despite subscriber growth, while US churn remains stable at 2%. Apptopia reported a 16.6% annual increase in inactive US subscribers in Q3.
• Netflix (NFLX), Microsoft (MSFT) - Netflix offered Microsoft USD 500mln to license Xbox video games for streaming adaptations, according to Puck News. Xbox CEO Asha Sharma reportedly countered with a proposal worth USD 800mln. The negotiations follow Microsoft’s recent launch of its XP division to oversee adaptations of its gaming franchises.

• Volkswagen (VWAGY) - Volkswagen’s Audi plans to invest approximately USD 4bln in its first US manufacturing plant in Georgia, creating around 4,500 jobs. Construction is scheduled to begin in 2027, with production starting in the early 2030s. The facility will have annual capacity of up to 200K vehicles, focusing on premium SUVs tailored to North American customers.
• BYD (BYDDF), Hyundai’s (HYMTF) - BYD is expanding in South Korea by targeting price-sensitive consumers with low-cost electric and hybrid vehicles, according to Bloomberg. BYD’s sales surged ninefold between January and August, while rival Hyundai recorded a 6% decline in comparable sales over the same period.

• SpaceX (SPCX), Nvidia (NVDA) - Elon Musk claims SpaceX closed USD 40bln in debt financing for Nvidia GPUs, although pricing negotiations remain ongoing, according to Bloomberg. Goldman Sachs (GS) is leading discussions with investors including Apollo Global Management (APO), while Pimco (ALIZY) has considered participating. Musk also warned that debt markets have almost entirely closed to neocloud operators lacking substantial revenues outside AI data centres, raising the prospect of widespread failures and consolidation; he predicted that few of the more than 200 neocloud companies would survive. SpaceX, by contrast, benefits from Starlink and launch revenues, although its own credit-default swaps reached a record 266bps, the article notes.
• Boeing (BA) - Boeing’s 777 freighter production has been halted for nearly two months following a pricing dispute with sole supplier Vaero, according to Reuters. The disruption also affected 767 production, including KC-46 tankers, costing up to USD 6.5mln daily. Despite a September settlement, 777 freighter production remains suspended.
• Fluor (FLR) - Fluor was awarded a USD 2.41bln contract modification by the US Navy for naval nuclear propulsion work at the Naval Nuclear Laboratory.
• Lockheed Martin (LMT) - Lockheed Martin received a USD 114.63mln US Navy contract to redesign, integrate and test two F-35 navigation systems, replacing obsolete components to prevent production disruptions.
• Kone (KNEBV FH) - Kone is reportedly planning EUR 4-5bln in asset disposals to secure antitrust clearance for its proposed deal with TK Elevator, according to the FT.

• Niger Crude - Algeria’s parliament approved President Tebboune’s proposal to deploy troops to protect oil facilities in Niger, where Sonatrach is drilling, according to Bloomberg. The rare overseas deployment strengthens Algeria’s support for Niger’s military government, following its dispatch of four fighter jets in August after a failed mutiny. Analysts said the move reflects Algeria’s efforts to reassert regional influence.
• Alaska LNG - Alaska LNG developer Polar Train LNG received financing and operational direction from sanctioned Russian energy firm Novatek before securing US Treasury approval, former CEO Joel Riddle alleged, according to the FT. Polar LNG denies wrongdoing and says it complies with US laws. Several executives resigned. Gas deliveries are targeted for 2030.

• Teck Resources (TECK) - United Steelworkers Local 7619 has begun strike action at its Highland Valley Copper Operations in British Columbia. Operations are continuing at reduced capacity, with the impact on production dependent on the strike’s duration. Teck has activated contingency plans.

• JPMorgan (JPM) - JPMorgan is deploying AI across private banking to streamline client onboarding, investment research and adviser productivity, according to Bloomberg. Despite efficiency gains, EMEA head Pablo Garnica expects adviser headcount to grow 10-15% over the next three to five years.
• MarketAxess Holdings (MKTX), Intercontinental Exchange (ICE) - MarketAxess said three shareholder lawsuits and 15 demand letters challenging disclosures related to its merger with Intercontinental Exchange are without merit. The complaints seek additional disclosures and could delay the transaction. MarketAxess has voluntarily supplemented its proxy statement without admitting wrongdoing, ahead of the shareholder vote on 29th October.

• Bayer (BAYRY) - Bayer announced new ESMO 2026 data showing NUBEQA reduced the risk of metastasis or death by 58% when added to androgen deprivation therapy and radiotherapy in prostate cancer patients at high risk of recurrence. At 3.8 years’ median follow-up, four-year metastasis-free survival reached 95% with NUBEQA versus 88% with placebo.
• AstraZeneca (AZN), Amgen (AMGN) - AstraZeneca reported positive Phase III IMFINZI results in two cancer trials. DeLLphi-305 showed IMFINZI plus Amgen’s tarlatamab reduced death risk by 58% and progression risk by 66%, with median survival of 21.1 months versus 12.7. VOLGA showed IMFINZI plus enfortumab vedotin reduced death risk by 42% and disease progression, recurrence, failure to undergo surgery or death by 49%.
• AstraZeneca (AZN) - AstraZeneca reported positive Phase III SAFFRON results, with Tagrisso plus savolitinib reducing disease progression or death by 45% and death risk by 32% versus chemotherapy in EGFR-mutated non-small cell lung cancer. Median progression-free survival reached 7.6 months (vs. 5.4), while overall survival improved by 4.9 months. One-year survival was 70% (vs. 53%).
• AstraZeneca (AZN) - AstraZeneca reported positive Phase III CLARITY-Gastric01 results, with sonesitatug vedotin reducing death risk by 42% versus standard treatment in previously treated Claudin 18.2-positive advanced gastric and related cancers. Death risk fell 53% in third- and later-line patients, while median overall survival doubled. The trial assessed patients with Claudin 18.2 expression in at least 25% of tumour cells.
• Pfizer (PFE) - Pfizer reported positive Phase 2 results for its investigational 25-valent pneumococcal vaccine in infants, demonstrating robust immune responses across all 25 serotypes and safety comparable to PREVNAR 20. Responses against serotype 3 were 8.8-fold higher after the third dose and approximately 15-fold higher after the fourth dose versus PREVNAR 20.
• Eli Lilly (LLY) - Eli Lilly reported Phase 1 data showing sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a 79% confirmed response rate and 100% disease control rate in platinum-sensitive ovarian cancer. Efficacy was maintained across FRalpha expression levels and in patients previously treated with PARP inhibitors. Sofe-M is undergoing multiple Phase 3 trials in ovarian cancer.
• Eli Lilly (LLY), Merck (MRK) - Eli Lilly reported ESMO data showing olomorasib plus Merck’s Keytruda achieved durable responses in first-line KRAS G12C-mutant lung cancer. Median progression-free survival and response duration remained unreached after nearly 21 months. Separately, olomorasib plus chemoimmunotherapy achieved a 62% response rate and median response duration of 14.5 months.
• Johnson & Johnson (JNJ) - Johnson & Johnson reported Phase 3 PROTEUS substudy results showing apalutamide plus androgen deprivation therapy before and after surgery reduced disease recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer. The regimen also reduced metastasis or death risk by 51% and delayed the need for subsequent treatment.
• Johnson & Johnson (JNJ) - Johnson & Johnson reported Phase 1b/2 OrigAMI-4 results showing durable responses with first-line RYBREVANT FASPRO plus a PD-1 inhibitor and fixed-duration carboplatin in recurrent or metastatic head and neck squamous cell carcinoma. At the clinical cutoff, 65% of responses remained ongoing. The findings support continued evaluation of the regimen in an ongoing Phase 3 trial.
• Johnson & Johnson (JNJ) - Johnson & Johnson reported Phase 1 results showing JNJ-6143 achieved a 75% confirmed response rate in heavily pretreated advanced prostate cancer patients with measurable disease. At the 50mg dose, 77% achieved PSA reductions of at least 50%, while 48% achieved reductions of at least 90%. Most treatment-related adverse events were mild to moderate.
• Regeneron Pharmaceuticals (REGN) - Regeneron Pharmaceuticals reported longer-term Phase 3 C-POST data showing Libtayo reduced the risk of death by 37%, versus 14% previously, in high-risk cutaneous squamous cell carcinoma patients following surgery and radiation. Nearly four years of follow-up confirmed sustained disease-free survival benefits, despite 88% of placebo patients crossing over to Libtayo upon recurrence.
• GSK (GSK) - GSK reported positive results from two cancer trials. Phase II AZUR-1 showed Jemperli achieved a 76% complete response rate in locally advanced rectal cancer, with no recurrences among responders. Phase I BEHOLD-1 showed Mo-Rez achieved a 62% response rate in platinum-resistant ovarian cancer, with median response duration of 12.2 months and progression-free survival of 11.1 months.
• Roche (RHHBY) - Genentech reported positive Phase III Krascendo 1 results, with divarasib reducing death risk by 44% versus sotorasib or adagrasib in previously treated KRAS G12C-mutated non-small cell lung cancer. Median overall survival reached approximately 18 months versus 12 months. The trial met primary and key secondary endpoints, with no new safety findings.
• Genmab (GMAB) - Genmab reported updated Phase 2 results for petosemtamab combined with FOLFOX or FOLFIRI in metastatic colorectal cancer. Objective response rates reached 75% in first-line and 67% in second-line treatment, rising to 81% among first-line patients with left-sided tumours. Longer follow-up confirmed most previously unconfirmed responses, supporting its ongoing Phase 3 programme.
• Incyte (INCY), Genmab (GMAB) - Incyte and Genmab announced a clinical trial collaboration evaluating Incyte’s investigational KRAS G12D inhibitor INCB161734 alongside Genmab’s petosemtamab and standard chemotherapy as a first-line treatment for metastatic colorectal cancer patients with KRAS G12D mutations.
• Amarin (AMRN) - Amarin reported that the Phase 3 EPA for Metastasis Trial 2, sponsored by the University of Leeds, failed to meet its primary progression-free survival endpoint. Median progression-free survival was 13.5 months with VAZKEPA/VASCEPA versus 12.9 months with placebo. However, the trial demonstrated a statistically significant overall survival benefit, meeting its prespecified key secondary endpoint.
• BioNTech (BNTX), Bristol Myers Squibb (BMY) - BioNTech and Bristol Myers reported Phase 2 ROSETTA Lung-107 results showing pumitamig plus docetaxel achieved a 36.7% confirmed response rate in previously treated metastatic non-small cell lung cancer. Median progression-free survival reached 6.9 months, compared with under four months typically seen with standard docetaxel treatment.

Opening sheets of this kind matter less for any single line than for the calendar they lay out: a week stacked with five major central bank decisions, a plenum in Beijing, a UK budget, US GDP and PCE, and the first of the megacap tech prints is the sort of compression where positioning historically runs light into the middle of the week and conviction gets rebuilt after the Fed sets the tone. The Ifo and the regional Fed surveys in the day ahead are second-tier by comparison; prints of that rank have tended to move Bunds and the front of the Treasury curve only when they break decisively with trend, and supply in the 2-year plus the buyback announcement is the more mechanical driver of afternoon price action. On the corporate tape, the GPU financing and HBM4 headlines extend a pattern that has defined this cycle, where ever-larger circular funding structures between AI buyers, lenders and chip suppliers keep the equity complex hostage to credit conditions in a way earlier tech capex waves were not. The Boeing supplier halt fits the established aerospace sequence: sole-source disputes tend to resolve on price within a quarter, with the daily cost accruing to the supplier's leverage rather than the airframer's backlog. Iran commentary and the Strait of Hormuz proposal are the familiar rhythm of headline-driven crude risk premia, where spikes on rhetoric have historically faded absent actual disruption to flows. The follow-ons are the plenum readouts, any shift in BoC and RBNZ tone ahead of their meetings, and whether the tech earnings slate validates or punctures the AI funding narrative running through today's tape.